CVE-2023-47718

IBM Maximo Asset Management cross-site request forgery

Description

IBM Maximo Asset Management 7.6.1.3 and Manage Component 8.10 through 8.11 is vulnerable to cross-site request forgery which could allow an attacker to execute malicious and unauthorized actions transmitted from a user that the website trusts. IBM X-Force ID: 271843.

Category

4.3
CVSS
Severity: Medium
CVSS 3.1 •
EPSS 0.04%
Vendor Advisory ibm.com Vendor Advisory ibm.com Vendor Advisory ibmcloud.com
Affected: IBM Maximo Asset Management
Affected: IBM Maximo Asset Management Manage Component
Published at:
Updated at:

References

Link Tags
https://www.ibm.com/support/pages/node/7107738 patch vendor advisory
https://www.ibm.com/support/pages/node/7107740 patch vendor advisory
https://exchange.xforce.ibmcloud.com/vulnerabilities/271843 vdb entry vendor advisory

Frequently Asked Questions

What is the severity of CVE-2023-47718?
CVE-2023-47718 has been scored as a medium severity vulnerability.
How to fix CVE-2023-47718?
To fix CVE-2023-47718, make sure you are using an up-to-date version of the affected component(s) by checking the vendor release notes. As for now, there are no other specific guidelines available.
Is CVE-2023-47718 being actively exploited in the wild?
As for now, there are no information to confirm that CVE-2023-47718 is being actively exploited. According to its EPSS score, there is a ~0% probability that this vulnerability will be exploited by malicious actors in the next 30 days.
What software or system is affected by CVE-2023-47718?
CVE-2023-47718 affects IBM Maximo Asset Management, IBM Maximo Asset Management Manage Component.
This platform uses data from the NIST NVD, MITRE CVE, MITRE CWE, First.org and CISA KEV but is not endorsed or certified by these entities. CVE is a registred trademark of the MITRE Corporation and the authoritative source of CVE content is MITRE's CVE web site. CWE is a registred trademark of the MITRE Corporation and the authoritative source of CWE content is MITRE's CWE web site.
© 2025 Under My Watch. All Rights Reserved.